Literature DB >> 21315210

The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: a pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST.

Cynthia M Westerhout1, Eric Bonnefoy, Robert C Welsh, Philippe Gabriel Steg, Florent Boutitie, Paul W Armstrong.   

Abstract

BACKGROUND: The CAPTIM trial suggested a survival benefit of prehospital fibrinolysis (FL) compared to primary percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (STEMI) with a presentation delay of <2 hours. We examined the relationship between reperfusion strategy and time from symptom onset on 1-year mortality in a combined analysis of 1,168 patients with STEMI.
METHODS: Individual patient data from CAPTIM (n = 840, 1997-2000) and the more recent WEST trial (n = 328, 2003-2005) were pooled.
RESULTS: Median age was 58 years, 81% were men, and 41% had anterior myocardial infarction; 640 patients were randomized to FL versus 528 patients to PCI. Both arms received contemporary adjunctive medical therapy. Presentation delay (ie, symptom onset to randomization) was similar in FL and PCI patients (median 105 [72-158] vs 106 [74-162] minutes, P = .712). Rescue PCI after FL occurred in 26% and 27%, and 30-day PCI, in 70% and 71% in CAPTIM and WEST, respectively. Mortality was not different between FL and PCI (4.6% vs 6.5%, P = .263); however, the interaction between presentation delay and treatment was significant (P = .043). Benefit with FL was observed with time <2 hours (2.8% [FL] vs 6.9% [PCI], P = .021, hazard ratio [HR] 0.43, 95% CI 0.20-0.91), whereas beyond 2 hours, no treatment difference was observed (6.9% [FL] vs 6.0% [PCI], P = .529, HR 1.23, 95% CI 0.61-2.46).
CONCLUSIONS: A strategy of early FL demonstrated a reduction in 1-year mortality compared to primary PCI in early presenters. Time from symptom onset should be a key consideration when selecting reperfusion therapy for STEMI.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21315210     DOI: 10.1016/j.ahj.2010.10.033

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  16 in total

1.  One-year mortality in patients with acute ST-elevation myocardial infarction in the Vienna STEMI registry.

Authors:  Bernhard Jäger; Serdar Farhan; Karim Kalla; Helmut D Glogar; Günter Christ; Ronald Karnik; Georg Norman; Herbert Prachar; Wolfgang Schreiber; Alfred Kaff; Andrea Podczeck-Schweighofer; Franz Weidinger; Thomas Stefenelli; Georg Delle-Karth; Anton N Laggner; Gerald Maurer; Kurt Huber
Journal:  Wien Klin Wochenschr       Date:  2015-07-11       Impact factor: 1.704

2.  Outcome up to one year following different reperfusion strategies in acute ST-segment elevation myocardial infarction: the Helsinki-Uusimaa Hospital District registry of ST-Elevation Acute Myocardial Infarction (HUS-STEMI).

Authors:  Juho Viikilä; Jyrki Lilleberg; Ilkka Tierala; Mikko Syvänne; Markku Kupari; Veikko Salomaa; Markku S Nieminen
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-08-21

3.  The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy.

Authors:  Yacine Boulaftali; Lamia Lamrani; Marie-Catherine Rouzaud; Stéphane Loyau; Martine Jandrot-Perrus; Marie-Christine Bouton; Benoît Ho-Tin-Noé
Journal:  Thromb Haemost       Date:  2012-03-08       Impact factor: 5.249

4.  ADAMTS13 exerts a thrombolytic effect in microcirculation.

Authors:  Marilena Crescente; Grace M Thomas; Melanie Demers; Jaymie R Voorhees; Siu Ling Wong; Benoit Ho-Tin-Noé; Denisa D Wagner
Journal:  Thromb Haemost       Date:  2012-07-10       Impact factor: 5.249

Review 5.  Recent advances in the diagnosis and treatment of acute myocardial infarction.

Authors:  Koushik Reddy; Asma Khaliq; Robert J Henning
Journal:  World J Cardiol       Date:  2015-05-26

6.  Outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention or pharmacoinvasive strategy in a Latin American country.

Authors:  Manuel Chacón-Diaz; Piero Custodio-Sánchez; Paol Rojas De la Cuba; Germán Yábar-Galindo; René Rodríguez-Olivares; David Miranda-Noé; Luis Marcos López-Rojas; Akram Hernández-Vásquez
Journal:  BMC Cardiovasc Disord       Date:  2022-06-29       Impact factor: 2.174

7.  Reperfusion delay in patients treated with primary percutaneous coronary intervention: insight from a real world Danish ST-segment elevation myocardial infarction population in the era of telemedicine.

Authors:  Mikkel M Schoos; Maria Sejersten; Anders Hvelplund; Mette Madsen; Jacob Lønborg; Jacob Steinmetz; Philip M Treschow; Frants Pedersen; Erik Jørgensen; Peer Grande; Henning Kelbæk; Peter Clemmensen
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-09

8.  Resolvin D1, a metabolite of omega-3 polyunsaturated fatty acid, decreases post-myocardial infarct depression.

Authors:  Kim Gilbert; Judith Bernier; Roger Godbout; Guy Rousseau
Journal:  Mar Drugs       Date:  2014-11-13       Impact factor: 5.118

Review 9.  Prehospital fibrinolysis versus primary percutaneous coronary intervention in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Vincent Roule; Pierre Ardouin; Katrien Blanchart; Adrien Lemaitre; Julien Wain-Hobson; Damien Legallois; Joachim Alexandre; Rémi Sabatier; Paul Milliez; Farzin Beygui
Journal:  Crit Care       Date:  2016-11-05       Impact factor: 9.097

10.  Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction?

Authors:  Jay Shavadia; Yinggan Zheng; Neda Dianati Maleki; Kurt Huber; Sigrun Halvorsen; Patrick Goldstein; Anthony H Gershlick; Robert Wilcox; Frans Van de Werf; Paul W Armstrong
Journal:  J Am Heart Assoc       Date:  2015-08-24       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.